Securetech Innovations, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Securetech Innovations, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.72M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $14.2K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $48.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $46.8K | May 1, 2024 |
| FY2022 | Dec 31, 2021 | $31.7K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $20.3K | Mar 30, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $10.8K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $35.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $34.1K | May 1, 2024 |
| FY2022 | Dec 31, 2021 | $22.8K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $14.4K | Mar 30, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $203.3K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($409.4K) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($368.5K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($480.9K) | May 1, 2024 |
| FY2022 | Dec 31, 2021 | ($108.7K) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($64.4K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($61.3K) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($168.5K) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($52.8K) | Feb 19, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $235.7K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($403.6K) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($368.3K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($482.3K) | May 1, 2024 |
| FY2022 | Dec 31, 2021 | ($108.7K) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($64.4K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($61.3K) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($168.5K) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($52.8K) | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.3K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $8.5K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.1K | May 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.2K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $430 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $9.0K | Mar 18, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.6K | Mar 25, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.89M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.6K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $24.2K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $201.0K | May 1, 2024 |
| FY2022 | Dec 31, 2021 | $254.0K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $138.8K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $134.6K | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $195.9K | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $155.6K | Feb 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.12M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $443.7K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $173.1K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $25.6K | May 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.5K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $2.8K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $100 | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $100 | Feb 21, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.77M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($440.0K) | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $148.9K | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $175.4K | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $250.5K | May 1, 2024 |
| FY2022 | Dec 31, 2020 | $136.0K | Apr 13, 2023 |
| FY2021 | Dec 31, 2019 | $134.5K | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $195.8K | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | $155.6K | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.98M | Mar 25, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.60M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($1.71M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($1.31M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($936.7K) | May 1, 2024 |
| FY2022 | Dec 31, 2021 | ($455.7K) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($347.0K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($282.6K) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($221.3K) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($52.8K) | Feb 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.8K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $6.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $138.3K | May 1, 2024 |
| FY2022 | Dec 31, 2021 | $214.0K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $89.8K | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $133.1K | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $195.9K | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | $155.6K | Feb 21, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 13, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31.38M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 78.09M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 79.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 111.84M | May 1, 2024 |
| FY2021 | Mar 29, 2022 | 111.64M | Mar 30, 2022 |
| FY2022 | Dec 31, 2021 | 113.34M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | 170.44M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 170.00M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 172.50M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 183.05M | Feb 19, 2019 |